Skip to main content
Industry News
94% response rate reported for COVID-19 vaccine candidate

Preliminary results have been reported by Inovio Pharmaceuticals from an early-stage trial of the COVID-19 vaccine candidate INO-4800 in a cohort of 40 healthy adults. Data showed 94% of 36 eligible participants registered immunological responses, and a Phase II/III study is planned for this summer.

Full Story: